Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Anagrelide
Drug ID BADD_D00139
Description Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms.[L14153] It is an oral imidazoquinazoline that was first approved for use in the US in 1997.[A214274] It appears to carry a better response rate than other thrombocythemia treatments (e.g. [busulfan], [hydroxyurea]) and may be better tolerated.[A214274]
Indications and Usage Anagrelide is indicated for the treatment of thrombocythemia, secondary to malignant neoplasms, to reduce platelet count and the associated risk of thrombosis. It is also beneficial in the amelioration of thrombocythemia symptoms including thrombo-hemorrhagic events.[L14153]
Marketing Status approved
ATC Code L01XX35
DrugBank ID DB00261
KEGG ID D07455
MeSH ID C021139
PubChem ID 135409400
NDC Product Code 13668-462; 13668-453
UNII K9X45X0051
Synonyms anagrelide | Agrylin | BL 4162A | Agrelin | anagrelide hydrochloride | imidazo(2,1-b)quinazolin-2(3H)-one, 6,7-dichloro-1,5-dihydro-, monohydrochloride | 6,7-dichloro-1,5-dihydroimidazo(2,1-b)quinazolin-2(3H)-one hydrochloride
Chemical Information
Molecular Formula C10H7Cl2N3O
CAS Registry Number 68475-42-3
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.001--Not Available
Abdominal pain07.01.05.002--
Acute myocardial infarction24.04.04.001; Available
Amblyopia06.02.01.001--Not Available
Angina pectoris24.04.04.002;
Aphthous ulcer07.05.06.002--Not Available
Arrhythmia02.03.02.0010.000168%Not Available
Arrhythmia supraventricular02.03.03.001--Not Available
Asthenia08.01.01.001--Not Available
Asthma22.03.01.002; Available
Atrial fibrillation02.03.03.002--
Atrioventricular block complete02.03.01.003--
Back pain15.03.04.005--
Blood creatinine increased13.13.01.004--
Body temperature increased13.15.01.001--Not Available
Bone pain15.02.01.001--
Breast cancer21.05.01.003; Available
Cardiac arrest02.03.04.0010.000280%
Cardiac failure02.05.01.0010.000112%
Cardiac failure congestive02.05.01.002--Not Available
Cardio-respiratory arrest22.02.06.007; Available
Cardiomegaly02.04.02.001--Not Available
Cardiomyopathy02.04.01.0010.000112%Not Available
Cardiovascular disorder02.11.01.010; Available
The 1th Page    1 2 3 4 5    Next   Last    Total 7 Pages
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene